Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Farmers Insurance
US Department of Justice
Queensland Health
US Army
Citi

Generated: August 24, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,579,359

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,579,359
Title:Method of treating prostate cancer with GnRH antagonist
Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Inventor(s): Olesen; Tine Kold (New York, NY), Persson; Bo-Eric (Rolle, DK), Cantor; Per (Charlottenlund, DK), van der Meulen; Egbert A (Dalby, SE), Jensen; Jens-Kristian Slott (Bagsvaerd, DK)
Assignee: FERRING B.V. (Hoofdorp, NL)
Application Number:14/139,922
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,579,359

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-001 Dec 24, 2008 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT ➤ Sign Up
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-002 Dec 24, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,579,359

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08250703Feb 29, 2008

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
QuintilesIMS
Farmers Insurance
Colorcon
Citi
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.